Maererano nekuongorora kwakabudiswa muNew England Journal of Medicine yakabudiswa muna July 5, Cabozantinib's general and progression-free live muvarwere vane advanced hepatocellular carcinoma yakanga iri nani kupfuura boka re placebo.
Dr. Ghassan K. Abou-Alfa kubva kuChirangaridzo Sloan Cancer Center muNew York City uye vashandi vakashandura varwere ve707 vane advanced hepatocellular carcinoma kuti vagamuchire carbotinib kana kufanana ne placebo mu 2 kusvika ku1 ratio. Vatori vechikamu vakanga vagamuchira sorafenib kurapwa uye vaine chirwere chekuwedzera mushure meimwe kana kupfuura maitiro ekurapa kwehepatocellular carcinoma.
Pakati pekuongorora kwepakati pechirongwa chechipiri, kutongwa kwakaratidza kuti kupona kwecarbotinib kwaive kureba kupfuura kweiyo placebo.
Vatsvakurudzi vakaona kuti kurarama kwepakati nepakati kwecarbotinib uye placebo kwaive gumi nemaviri ne10.2 mwedzi, zvichiteerana (ngozi yenjodzi yekufa yaive 8.0). Zve carbotinib uye placebo, iyo yepakati-yekuenderera-isina kupona yaive 0.76 uye 5.2 mwedzi, zvichiteerana. 1.9% uye 68% yevarwere vari muboka re carbotinib neboka re placebo vane ruzivo rwegiredhi 36 kana 3 zviitiko zvakashata, zvichiteerana. Zviitiko zvakajairika zvepamusoro-soro ndeyemichindwe-yakasimwa erythema kunzwa, kukwirisa kweropa, mazinga akakwirisa easpartate aminotransferase, kuneta uye manyoka, zvese izvi zvakajairika necarbatinib.
Vanyori vanonyora, "Mune varwere vane advanced hepatocellular carcinoma yakamborapwa, kurapwa ne carbotinib kunogona kukonzera kupona kwenguva refu uye kufambira mberi- kusununguka pane placebo."
https://www.drugs.com/news/cabozantinib-improves-survival-advanced-hepatocellular-cancer-75490.html
